Data from: Distinct SCI-Related Adverse-Event Reporting Signals Associated with Methylprednisolone and Ciprofloxacin: A FAERS-Based Pharmacovigilance and Network Toxicology Study

It comprises two parts.The first part is the FAERS-derived analytic dataset and the R analysis code. Based on the U.S. FDA Adverse Event Reporting System (FAERS, Q1 2023 to Q1 2026, deduplicated N = 4,566,101 reports), we computed reporting disproportionality metrics (ROR, PRR, EBGM, IC) for methylprednisolone (MP) and ciprofloxacin (CIP) associated spinal cord injury (SCI).

The outputs cover the main analysis, sex-stratified and age-stratified analyses, combined analysis, VigiAccess external consistency checks, and consistency analysis, and include the plotting data for Figure 1 and Figure 2. The script faers_analysis_v7_clean.R reproduces all derived analytic tables from the raw FAERS quarterly files.The second part contains the molecular docking results. It includes the binding affinities (ΔG, Kd) of MP and CIP against ten candidate target proteins (NR3C1, NR3C2, ROCK1, ROCK2, SLC7A11, NFKB1, TOP2A, TOP2B, SDHA, SOD1), the data corresponding to Table 7, the SDF structure of the methylprednisolone ligand, and three Python scripts for docking analysis, result summarization, and CIP-specific docking.